Pharma BD Deal Intelligence
BMS never acquired ImClone—it paid roughly $1.0B for a 19.9% equity stake plus up to $1.0B in milestones for Erbitux, which became a genuine blockbuster reaching $1.3B in worldwide sales by 2008. BMS lost the asset entirely when Eli Lilly won a 2008 bidding war for ImClone at ~$6.5B, and BMS fully exited North American rights by 2015.
BMS never acquired ImClone outright — it bought a ~20% equity stake plus a co-promotion alliance for Erbitux, which became a real oncology blockbuster, but BMS lost control of the asset entirely when Eli Lilly won the 2008 bidding war and BMS exited North American rights by 2015.
Full analysis, sources & comparables →CEO Peter Dolan: 'ImClone Systems' IMC-C225 represents one of the most important advances in cancer medicine since the introduction of TAXOL in 1991... focuses…
Analyst Krensavage said Erbitux 'could have carried them through the patent expirations, but without it they faltered. The ImClone problem reflected their…
The 2001 BMS-ImClone deal was renegotiated in 2002 after an FDA Refuse-to-File letter, and BMS later acquired ImClone outright in 2008 for $6.5B at $70/share.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
BMS-ImClone Erbitux (cetuximab) co-development/commercialization; $1B equity tender at 75% premium for 19.9% stake plus $1B in milestones. Renegotiated 2002 after FDA RTF letter.
BMS never acquired ImClone outright — it bought a ~20% equity stake plus a co-promotion alliance for Erbitux, which became a real oncology blockbuster, but BMS lost control of the asset entirely when Eli Lilly won the 2008 bidding war and BMS exited North American rights by 2015.
Assessment window: 15yr post-close.
159K US cases/yr
Colorectal cancer is the fourth most common cancer in the US, with metastatic disease historically carrying poor 5-year survival. Cetuximab targeted EGFR-overexpressing tumors — initially a broad subset, later restricted to KRAS wild-type after biomarker science matured. Squamous cell head and neck cancer was a secondary target indication where EGFR signaling is also a key driver.
When BMS struck the September 2001 ImClone deal, the metastatic colorectal cancer treatment paradigm was shifting from 5-FU monotherapy toward combination regimens with irinotecan (Camptosar, Pharmacia/Pfizer) and oxaliplatin (Eloxatin, Sanofi-Synthelabo, US approval 2002). Targeted biologics had not yet arrived — Genentech's Avastin (bevacizumab) would not gain mCRC approval until February 2004, the same month Erbitux finally cleared FDA. ImClone's Erbitux (cetuximab) was a chimeric IgG1 anti-EGFR mAb in Phase 3 development. BMS paid an aggressive ~$1B to acquire 19.9% of ImClone at $70/share — a 75% premium — plus up to $1B in development/regulatory/commercial milestones, signaling that BMS viewed Erbitux as a pipeline-replacing oncology asset given imminent patent cliffs on Taxol and other franchises. The deal collapsed in narrative when FDA issued a Refuse-to-File letter on the BLA in December 2001, triggering an insider-trading scandal involving ImClone CEO Sam Waksal and Martha Stewart. BMS recorded an ~$875M loss and renegotiated terms in 2002. Erbitux ultimately reached market in February 2004 and gained head & neck cancer approval in March 2006. Competing anti-EGFR Vectibix (panitumumab) followed in 2006.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / ImClone Systems Incorporated (this deal) | 2001 | $2.0B | 61 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |